Pretreatment immunoscore and an inflamed tumor microenvironment (TME) are associated with efficacy in patients (Pts) with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel) in ZUMA-1

被引：7

作者：

Rossi, John M. ^{[1
]}

Galon, Jerome ^{[2
]}

Chang, Edmund ^{[1
]}

Perbost, Regis ^{[3
]}

Scholler, Nathalie ^{[1
]}

Turcan, Sarah ^{[3
]}

Danan, Corinne ^{[3
]}

Locke, Frederick L. ^{[4
]}

Neelapu, Sattva S. ^{[5
]}

Miklos, David B. ^{[6
]}

Jacobson, Caron A. ^{[7
]}

Lekakis, Lazaros J. ^{[8
]}

Lin, Yi ^{[9
]}

Ghobadi, Armin ^{[10
]}

Milletti, Francesca ^{[1
]}

Go, William Y. ^{[1
]}

Bot, Adrian ^{[1
]}

机构：

[1] Kite, Santa Monica, CA USA

[2] UPMC Univ Paris, Sorbonne Univ, Univ Paris Descartes, INSERM, Marseille, France

[3] HalioDx, Paris, France

[4] H Lee Moffitt Canc Ctr & Res Inst, Blood & Marrow Transplantat, Tampa, FL USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[6] Stanford Univ, Sch Med, Blood & Marrow Transplantat, Stanford, CA 94305 USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Univ Miami Hlth Syst, Sylvester Comprehens Canc Ctr, Miami, FL USA

[9] Mayo Clin, Div Hematol, Rochester, MN USA

[10] Washington Univ, Sch Med, Div Med Oncol, St Louis, MO USA

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2019-CT153

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT153

引用

页数：3

共 50 条

[1] Retreatment of Patients With Refractory Large B Cell Lymphoma With Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
Locke, Frederick
Bartlett, Nancy
Jacobson, Caron
Oluwole, Olalekan
Munoz, Javier
Lekakis, Lazaros
Topp, Max
Avivi, Irit
Kim, Jenny
Chu, Rong
Zheng, Lianqing
Rossi, John
Bot, Adrian
Neelapu, Sattva
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S21 - S22
[2] Retreatment (reTx) of Patients with Refractory Large B Cell Lymphoma with Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
Locke, Frederick L.
Bartlett, Nancy L.
Jacobson, Caron A.
Oluwole, Olalekan O.
Munoz, Javier
Lekakis, Lazaros J.
Topp, Max S.
Avivi, Irit
Kim, Jenny J.
Chu, Rong
Zheng, Lianqing
Rossi, John M.
Bot, Adrian
Neelapu, Sattva S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S265 - S265
[3] Clinical Response in ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma, May Be Influenced by Characteristics of the Pretreatment Tumor Microenvironment (TME)
Rossi, John M.
Galon, Jerome
Turcan, Sarah
Danan, Corinne
Locke, Frederick L.
Neelapu, Sattva S.
Miklos, David B.
Jacobson, Caron A.
Lekakis, Lazaros J.
Lin, Yi
Ghobadi, Armin
Go, William Y.
Bot, Adrian
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S281 - S281
[4] Characteristics of the pretreatment tumor microenvironment may influence clinical response in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi-cel) in the pivotal ZUMA-1
Rossi, John M.
Galon, Jerome
Turcan, Sarah
Danan, Corinne
Locke, Frederick L.
Neelapu, Sattva S.
Miklos, David B.
Jacobson, Caron A.
Lekakis, Lazaros J.
Lin, Yi
Ghobadi, Armin
Go, William Y.
Bot, Adrian
CANCER RESEARCH, 2018, 78 (13)
[5] Retreatment (ReTx) of patients (Pts) with refractory large B cell lymphoma (LBCL) sith Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
Locke, F. L.
Bartlett, N. L.
Jacobson, C. A.
Oluwole, O. O.
Munoz, J.
Lekakis, L. J.
Topp, M. S.
Avivi, I
Kim, J. J.
Chu, R.
Zheng, L.
Rossi, J. M.
Bot, A.
Neelapu, S. S.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 57 - 57
[6] Axicabtagene Ciloleucel (Axi-Cel) In Patients With Refractory Large B Cell Lymphoma: Long-Term Safety and Efficacy of ZUMA-1
Neelapu, S. S.
Ghobadi, A.
Jacobson, C. A.
Miklos, D. B.
Lekakis, L. J.
Oluwole, O. O.
Lin, Y.
Braunschweig, I.
Hill, B. T.
Timmerman, J. M.
Deol, A.
Reagan, P. M.
Stiff, P.
Flinn, I. W.
Farooq, U.
Goy, A.
McSweeney, P. A.
Munoz, J.
Siddiqi, T.
Chavez, J. C.
Herrera, A. F.
Xue, A.
Jiang, Y.
Bot, A.
Rossi, J. M.
Kim, J. J.
Go, W. Y.
Locke, F. L.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 26 - 27
[7] Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
Locke, Frederick Lundry
Bartlett, Nancy L.
Jacobson, Caron A.
Oluwole, Olalekan O.
Munoz, Javier
Lekakis, Lazaros J.
Topp, Max S.
Avivi, Irit
Kim, Jenny J.
Chu, Rong
Zheng, Lianqing
Rossi, John M.
Bot, Adrian
Neelapu, Sattva Swarup
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.
Locke, Frederick Lundry
Ghobadi, Armin
Jacobson, Caron A.
Jacobsen, Eric D.
Miklos, David Bernard
Lekakis, Lazaros J.
Braunschweig, Ira
Oluwole, Olalekan O.
Lin, Yi
Siddiqi, Tanya
Deol, Abhinav
Reagan, Patrick Michael
Farooq, Umar
Bot, Adrian
Jiang, Yizhou
Rossi, John M.
Xue, Allen
Go, William Y.
Neelapu, Sattva Swarup
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[9] A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel [Axi-Cel]) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL)
Neelapu, Sattva S.
Locke, Frederick L.
Bartlett, Nancy L.
Lekakis, Lazaros J.
Reagan, Patrick M.
Miklos, David B.
Jacobson, Caron A.
Braunschweig, Ira
Oluwole, Olalekan O.
Siddiqi, Tanya
Lin, Yi
Crump, Michael
Kuruvilla, John
Van Den Neste, Eric
Farooq, Umar
Navale, Lynn
DePuy, Venita
Kim, Jenny J.
Gisselbrecht, Christian
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S232 - S232
[10] A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel; Axi-Cel) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL)
Neelapu, Sattva S.
Locke, Frederick L.
Bartlett, Nancy L.
Lekakis, Lazaros J.
Reagan, Patrick
Miklos, David B.
Jacobson, Caron A.
Braunschweig, Ira
Oluwole, Olalekan
Siddiqi, Tanya
Lin, Yi
Crump, Michael
Kuruvilla, John
Van den Neste, Erin
Farooq, Umar
Navale, Lynn
DePuy, Venita
Kim, Jenny
Gisselbrecht, Christian
MOLECULAR THERAPY, 2020, 28 (04) : 575 - 576

← 1 2 3 4 5 →